Introduction
============

Tardive dyskinesia (TD) is a severe[@b1-dddt-12-1215] and potentially irreversible adverse effect of first-and second-generation antipsychotics (FGAs and SGAs), with a cumulative annual incidence of 5.4%[@b2-dddt-12-1215] to 7.7%[@b3-dddt-12-1215] with FGAs compared to 0.8%[@b2-dddt-12-1215] to 3.0%[@b3-dddt-12-1215] with SGAs in adults, and approximately a 3- to 5-fold higher incidence in the elderly, with both FGAs (25%--30%)[@b4-dddt-12-1215],[@b5-dddt-12-1215] and SGAs (5%--7%).[@b6-dddt-12-1215] A recent meta-analysis found across 41 studies and 11,493 patients (77% diagnosed with schizophrenia) pooled TD prevalence of 25.3% in patients treated with antipsychotics, with a lower frequency with current SGA treatment (20.7%) than FGA treatment (30.0%), and the lowest prevalence in SGA-treated patients without a documented lifetime history of FGA treatment (7.2%).[@b7-dddt-12-1215] Proposed risk factors for TD include both unmodifiable patient-related and illness-related risk factors (higher age, female sex, Caucasian race, African descent, longer illness duration, intellectual disability and brain damage, negative symptoms in schizophrenia, mood disorder diagnosis, cognitive symptoms in mood disorders, and gene polymorphisms involving antipsychotic metabolism and dopamine functioning) as well as modifiable comorbidity-related and treatment-related factors (diabetes, smoking, alcohol and substance abuse, FGA vs SGA treatment, higher cumulative or current antipsychotic dose or higher antipsychotic plasma levels, early neuromotor syndromes \[parkinsonian side effects, acute dystonia\], anticholinergic co-treatment, akathisia, and subtle/emergent dyskinesia).[@b2-dddt-12-1215],[@b3-dddt-12-1215],[@b7-dddt-12-1215]--[@b10-dddt-12-1215]

TD can be measured with Abnormal Involuntary Movement Scale (AIMS),[@b11-dddt-12-1215] a 12-item scale with items 1--7 assessing involuntary movements across body regions, with a score ranging from 0 (no dyskinesia) to 4 (severe, maximal amplitude, and persistence during observation of abnormal movements), or with other less frequently used instruments/scales, such as the Extrapyramidal Symptom Rating Scale.[@b12-dddt-12-1215]

Although still not conclusively established, 3 main (non-mutually exclusive) pathogenetic hypotheses of TD have been proposed. These include oxidative stress,[@b13-dddt-12-1215] glutamate-mediated toxicity within striatopallidal or nigrostriatal GABA signaling pathways with decreased inhibitory activity in nigrostriatal circuits, and dopamine receptor hypersensitivity following receptor upregulation due to antidopaminergic treatment.[@b14-dddt-12-1215] The latter theory is supported by the worsening or un-masking of TD after abrupt cessation of dopamine D2 blocking agents.[@b15-dddt-12-1215]

TD should ideally be prevented. Strategies include antipsychotic prescription only when indicated clinically, avoiding parkinsonian side effects, using conservative maintenance doses, and preferring SGAs over FGAs as first-line treatment.[@b3-dddt-12-1215],[@b8-dddt-12-1215],[@b16-dddt-12-1215] However, SGAs are not a homogeneous class with regard to parkinsonian adverse effect rates.[@b17-dddt-12-1215] Nevertheless, the differential TD risk among individual SGAs, except for a likely lowest risk with clozapine, has not been clear. In this regard, a recent meta-analysis of annualized incidence rate ratios comparing FGAs with SGAs and SGAs with each other in RCTs lasting ≥3 months (median: 1.0 \[interquartile range =0.44--2.0\] years) not only confirmed significantly lower TD annualized incidence rates with SGAs as a class vs FGAs (NNT =20) but also suggested that olanzapine and aripiprazole may have a small, yet statistically significant advantage over other non-clozapine SGAs (NNT =100 for olanzapine vs non-clozapine SGAs).[@b18-dddt-12-1215] Moreover, in 3 trials that compared clozapine to olanzapine or predominant olanzapine treatment, olanzapine did not differ from clozapine with regard to annualized TD risk. Finally, despite a relatively greater risk of parkinsonian side effect and anticholinergic co-treatment than many other SGAs,[@b17-dddt-12-1215] risperidone and paliperidone had a similar TD risk when compared head-to-head with other non-clozapine/non-olanzapine SGAs.[@b18-dddt-12-1215]

When TD is present, a number of treatment approaches have been tested, including antipsychotic dose reduction, cessation, or switch to/prescription of specific antipsychotics; however, no convincing evidence supports such strategies,[@b19-dddt-12-1215] apart from a switch to clozapine when TD is diagnosed in patients with schizophrenia and ongoing antipsychotic treatment is needed.[@b20-dddt-12-1215],[@b21-dddt-12-1215] Nevertheless, clozapine is not easy to use,[@b22-dddt-12-1215] and when clozapine is withdrawn, TD seems to recur.[@b23-dddt-12-1215]

Several additional treatment approaches for improving TD symptoms exist that target alternatively proposed pathogenetic pathways, such as oxidative stress and impaired clearance of phenylalanine, with in some cases very early, promising results, such as for branched-chain amino acids, ginkgo biloba, vitamin E or melatonin,[@b24-dddt-12-1215]--[@b26-dddt-12-1215] but without definitive, large/high-quality trials to support their clinical use.

In addition, benzodiazepines, non-antipsychotic catecholaminergic agents, gamma-aminobutyric acid agonists, cholinergic or anticholinergic agents, or other miscellaneous treatments have been tested as augmentation strategies aimed at reducing TD severity, with almost no clinically relevant improvement[@b27-dddt-12-1215]--[@b32-dddt-12-1215] if not detrimental effect, or with tolerability issues, such as sedation, ataxia, or risks correlated with insulin administration outweighing any potentially beneficial effect.[@b29-dddt-12-1215],[@b30-dddt-12-1215],[@b33-dddt-12-1215] Lastly, preliminary evidence suggested relevant efficacy and notable safety of deep brain stimulation for TD[@b34-dddt-12-1215] and of botulinum for focal dystonias.[@b33-dddt-12-1215] A recent comprehensive systematic review assessing the quality and level of evidence of pharmacological approaches for TD concluded that "underpowered trials of limited quality repeatedly fail to provide answers."[@b35-dddt-12-1215]

Beyond stopping or modifying antipsychotic treatment or the aforementioned off-label approaches based on preliminary evidence, reversible vesicular monoamine transporter-2 (VMAT-2) inhibitors, which block a transporter that packages neurotransmitters, particularly dopamine, but also noradrenalin, serotonin, and histamine, into presynaptic vesicles for release into the synaptic cleft, have been tested for TD. Tetrabenzaine was the first VMAT-2 inhibitor that was approved in the United States in 2008 for Huntington's chorea and that has been used off-label for the treatment of TD,[@b15-dddt-12-1215],[@b36-dddt-12-1215] with promising results from observational studies.[@b37-dddt-12-1215] However, serum half-life of tetrabenazine is very short, requiring 3 times daily dosing and resulting in large peak-to-trough variations in plasma levels that have been associated with off-target adverse effects, such as akathisia, somnolence, and even depression and suicidality, for which a black box warning was required by the US Food and Drug Administration (FDA) in subjects suffering from Huntington's chorea.[@b38-dddt-12-1215],[@b39-dddt-12-1215] More recently, 2 novel VMAT-2 inhibitors, deutetrabenazine and valbenazine,[@b40-dddt-12-1215] have been developed, aiming at pharmacokinetic improvements (deutetrabenazine) or pharmacokinetic and pharmacodynamic improvements (valbenazine) over tetrabenazine. These modifications have resulted in a prolonged half-life and reduced peak--trough variations compared to tetrabenazine, and, in the case of valbenazine, eliminated enantiomers that are responsible for the off-target receptor occupancy unrelated to VMAT-2.[@b41-dddt-12-1215],[@b42-dddt-12-1215] Since both deutetrabenazine and valbenazine have been tested in double-blind, randomized, placebo-controlled trials (DBRPCTs) and were FDA approved for the treatment of TD in 2017, and since to our knowledge no formal meta-analysis has compared data from all available RCTs of VMAT-2-inhibitors, we conducted a systematic review and meta-analysis aiming at reporting on the meta-analytically derived evidence for the efficacy and safety of VMAT-2 inhibitors for the treatment of patients with TD. We hypothesized that VMAT-2 inhibitors, pooled together and individually, would be superior to placebo in the reduction of TD.

Materials and methods
=====================

Search strategy and inclusion criteria
--------------------------------------

An electronic literature search from database inception and without language restriction was performed on November 8, 2017, in the Cochrane library (<http://www.cochranelibrary>. com/), PubMed, FDA website (<https://www.fda.gov/>), and [ClinicalTrials.gov](https://clinicaltrials.gov/) (<https://ClinicalTrials.gov/ct2/home>), plus relevant conference abstracts. The following search keywords were used in PubMed, with equivalent/appropriate syntax for other databases: "tardive dyskinesia"\[All Fields\] AND ("tetrabenazine"\[All Fields\] OR "deutetrabenazine"\[All Fields\] OR "valbenazine"\[All Fields\]) AND (Review\[ptyp\] OR Clinical Trial\[ptyp\]). In addition, bibliographies of included or relevant references were hand-searched to seek further potentially eligible papers.

Inclusion criteria were: 1) most recent/comprehensive systematic review or meta-analysis on VMAT-2 inhibitors for TD, with included trials, or 2) individual, open, or randomized trials of VMAT-2 inhibitors for TD. For the formal meta-analysis, only data from DBRPCTs in patients with TD were considered, and only trials that reported results based on the AIMS scale were included.

In addition to the database search, data regarding the pharmacodynamic and pharmacokinetic properties of each drug were extracted from the official information provided by the manufacturers.

Two authors (MS and GP) independently conducted the search and selected the eligible papers. Any disagreement was resolved by consensus.

### Data extraction

Relevant information about efficacy, safety, and clinically relevant pharmacokinetic and pharmacodynamic information was abstracted from systematic reviews/meta-analyses, individual trials, or manufacturer's drug leaflets. Two authors (MS and GP) independently extracted the pharmacokinetic and pharmacodynamic properties of each VMAT-2 inhibitor, the number of studies (for reviews), study design, study duration, specific drug of interest, continuous and categorical efficacy data, and adverse effects frequencies. Any disagreement was resolved by consensus.

#### Quality assessment

Two authors (MS and GP) independently assessed the quality of the included studies with the Cochrane Collaboration's tool for assessing the risk of bias.[@b43-dddt-12-1215]

#### Meta-analysis

We performed a random effects meta-analysis[@b44-dddt-12-1215],[@b45-dddt-12-1215] by using comprehensive meta-analysis (CMA, version 2). For continuous variables, we calculated the standardized mean difference (SMD) as the primary outcome measure, complemented by the weighted mean difference (WMD) whenever the same rating scale was used across all trials. For categorical outcomes, we calculated the risk ratio (RR) and, whenever the RR result was statistically significant, the number-needed-to-treat or harm (NNT or NNH). Effect sizes were accompanied by their 95% confidence intervals (CIs). Heterogeneity was assessed with the Cochrane Q and *I*^2^ statistics for each analysis (with significant heterogeneity being indicated by a *p*\<0.05 or *I*^2^≥50%, respectively).[@b46-dddt-12-1215] We meta-analyzed each VMAT-2 inhibitor separately and also calculated pooled effect sizes. Publication bias was assessed via visual inspection of funnel plots and with the Begg-Mazumdar Kendall's tau[@b47-dddt-12-1215] and Egger bias test.[@b48-dddt-12-1215] In case that publication bias was suspected, we calculated the trim and fill adjusted analysis[@b49-dddt-12-1215] to remove the most extreme small studies from the positive side of the funnel plot and recalculated the effect size at each iteration until the funnel plot was symmetric around the (new/adjusted) effect size. In order to indirectly estimate any drug-related difference between VMAT-2 inhibitors, we also conducted sensitivity analyses based on the individual VMAT-2 inhibitor. In order to have a conservative approach and minimize biases, we used a "once randomized-analyzed," or intent-to-treat (ITT) approach for all efficacy and safety analyses and ignored the results from the completer analyses. The exception was a prespecified modified ITT approach in the studies with deutetrabenazine where all eligible and consenting subjects were randomized, but a priori only those with AIMS scores ≥6 were analyzed.

Results
=======

Search results
--------------

[Figure 1](#f1-dddt-12-1215){ref-type="fig"} presents the flow diagram of the literature search. Our search yielded no article from the Cochrane database but 41 individual studies and 3 reviews from PubMed, of which 33 were excluded after title/abstract assessment with finally 8 published studies and 3 reviews being included after full-text assessment. In [ClinicalTrials.gov](https://clinicaltrials.gov/), we identified 38 trials (DBRPCT and studies with a different design), of which 30 were excluded after full assessment of each trial results section on the website (with specific reasons for the exclusion of each trial reported in detail in [Table S1](#SD1-dddt-12-1215){ref-type="supplementary-material"}). In addition, 2 relevant conference abstracts were included.

Different articles reported results from the same trial, or from trials not registered in [ClinicalTrials.gov](https://clinicaltrials.gov/) (being too old), and some trials retrieved in [ClinicalTrisls.gov](http://ClinicalTrisls.gov) did not have related publications. Hence, we merged the information gathered from all eligible studies and reviews from PubMed with data reported in [ClinicalTrials.gov](https://clinicaltrials.gov/) and in conference abstracts, and finally included information from 8 distinct DBRPCTs, 2 controlled single-blind studies, 7 distinct open-label studies, and 3 distinct studies with a retrospective or case-series design.

In particular, of these 20 included articles, tetrabenazine was evaluated in 2 DBPRCTs (n=10), 1 haloperidol-controlled RCT (n=13), 1 single-blind placebo-controlled study (n=12), 5 open-label studies, and 3 retrospective or case-series studies (total n=409). Deutetrabenazine was evaluated in 2 DBPRCTs (drug=281, placebo=132) and one open label study (n=304). Finally, valbenazine was investigated in 4 DBRPCs (drug=281, placebo=207) and 1 open label study (n=163). Results from all 20 trials and studies are summarized in our systematic review.

Finally, we formally meta-analyzed the 2 DBRPCTs for deutetrabenazine (n=413), and 4 DBRPCTs for valbenazine (n=488). In addition, the pharmacokinetic characteristics of each included VMAT-2 inhibitor were retrieved from the specific medication's package insert sheet.

The main characteristics of the included studies are summarized in [Table 1](#t1-dddt-12-1215){ref-type="table"}. Below, we descriptively summa-rize the pharmacological properties, clinical indications, efficacy, and safety of each drug from individual studies (reported in detail in [Table 2](#t2-dddt-12-1215){ref-type="table"}), quality of included studies ([Table 3](#t3-dddt-12-1215){ref-type="table"}), and a summary of results from meta-analysis ([Table 4](#t4-dddt-12-1215){ref-type="table"}).

Tetrabenazine
-------------

### Pharmacokinetics and pharmacodynamics

The FDA approved tetrabenazine for Huntington's disease, not TD, in the United States, while the Agenzia Italiana del Farmaco approved tetrabenazine for TD in Italy along with several other countries including the United Kingdom and Canada. Tetrabenazine is composed of a one-to-one mixture of two enantiomers, alpha-tetrabenazine and beta-tetrabenazine. Each enantiomer is metabolized to 2 isomers. The (+)alpha and (-)alpha dihydrotetrabenazine (DHTBZ) isomers have VMAT-2 reversible inhibitory activity (affinity of tetrabenazine for VMAT-2 is Ki ≈100 nM), while the (+)beta and (-)beta DHTBZ isomers are weak dopamine D2 antagonists (Ki ≈2,100 nM). Tetrabenazine can be taken with or without food, and its bioavailability after oral administration is ≥75%, but its half-life is as short as 5 hours (thus 3 times daily dosing is required).[@b50-dddt-12-1215] The C~max~ is reached within 1--1.5 hours, with blood plasma peaks[@b50-dddt-12-1215] and protein binding being close to 85%. Tetrabenazine is extensively metabolized by CYP2D6 and 75% of it being eliminated in urine and around 16% in feces.

### Efficacy

One systematic review of the effects of tetrabenazine for TD[@b15-dddt-12-1215] reported results from 12 studies overall, with partially overlapping studies populations,[@b51-dddt-12-1215] with 2 DBRPCTs (n=10), 1 single-blind placebo-controlled study (n=12), and one haloperidol-controlled, randomized study (n=12). Each study had very small sample sizes, surprisingly with response rates up to 100% for tetrabenazine, and all used poor quality assessment tools and poor reporting of outcomes, precluding inclusion of any of these studies in our meta-analysis. Overall, considering also studies with open-label or retrospective design, 419 patients aged 20--82 years were studied. The study duration of the RCTs ranged from 1 to 20 weeks, and the tetrabenazine dose ranged between 50 and 150 mg/day. Notably, in 2 of the RCTs, which were conducted in the 1970s, patients had been on antipsychotic treatment (likely all FGAs) for \>10 years and had been hospitalized for an average of 29 years.[@b52-dddt-12-1215],[@b53-dddt-12-1215] Moreover, in just 1 trial, tetrabenazine was compared with an active control intervention, namely, haloperidol, without showing a benefit in TD reduction versus haloperidol.[@b53-dddt-12-1215] In one prospective, single-blind trial,[@b52-dddt-12-1215] dyskinesia "disappeared" in 1 out of 3 patients, "improved" in 1 out of 4 patients, and the average oral movements per minute significantly decreased from baseline and then re-increased to baseline values after tetrabenazine cessation.[@b52-dddt-12-1215] In a more "recent," single-blind, randomized trial (published in 1999),[@b54-dddt-12-1215] all patients reported at least mild improvement, and dyskinesia clearly improved from baseline.

Overall, there is a lack of high-quality double-blind randomized, placebo controlled RCTs, without convincing evidence of efficacy of tetrabenazine for TD. No "head to head" double-blind comparison with another VMAT-2 inhibitors has been performed.

### Safety and tolerability

Most of the safety data come from trials targeting conditions other than TD (eg, Huntington's disease). Generally, almost 9 out of 10 patients experienced ≥1 adverse effect during tetrabenazine treatment. In patients with TD, the most frequent adverse events (AEs) (\>10% and \>5% more frequent than placebo) were drowsiness (mean: 24.8%, range: 13%--36.5%), sedation/somnolence (mean: 18.5%, range: 6%--31%), parkinsonian side effects (mean: 11.9%, range: 4.3%--78.6%), insomnia (11%), anxiety (10.3%), depression (mean: 6.8%, range: 1.7%--11%), and akathisia (mean: 6.3%, range: 1.7%--9.5%). Sedation and acute motor syndromes (parkinsonian side effects, dystonic reaction, and akathisia), which can be due to D2 antagonism of the beta-isomers of tetrabenazine, have been reported in approximately 1 out of 4 patients.[@b54-dddt-12-1215] Also, based on data in Huntington's disease, tetrabenazine has a black box warning for depression and suicidality,[@b39-dddt-12-1215] leading to the recommendation that attention should be paid to mood status or aberrant acting out behavior during tetrabenazine treatment. Somnolence and sedation may impair driving abilities. QT prolongation may occur, but does not seem to be clinically relevant. Dysphagia can also occur, increasing the risk of pneumonia. Hyperprolactinemia may occur as well. Notably, in the trials included in the abovementioned systematic review,[@b15-dddt-12-1215] specifically targeting TD, 1 patient out of 24 did not complete the study due to psychotic exacerbation.[@b52-dddt-12-1215]

### Poor metabolizers, special populations, and concomitant drugs

As per FDA labeling, tetrabenazine dose should not exceed 50 mg/day in poor CYP2D6 metabolizers, or 100 mg/day in extensive metabolizers, yet no clear correlation has been demonstrated between CYP2D6 status and clinical response.[@b55-dddt-12-1215] Guidance from labels in other countries may differ. Tetrabenazine is contraindicated in patients with any degree of hepatic impairment, and in patients with suicidal ideation, or untreated/inadequately treated depression. Pregnant or lactating women should be warned that data from animal studies suggest possible fetal harm but that no data are available from human studies. The tetrabenazine dose should be decreased in case of co-treatment with CYP2D6 inhibitors (eg, paroxetine and fluoxetine), and tetrabenazine must not be co-administered with monoamine oxidase inhibitors (MAOIs) or reserpine (an irreversible VMAT inhibitor), due to possible toxicity related to partially overlapping pharmacodynamic actions. No efficacy or safety data are available for pediatric or geriatric populations.

Deutetrabenazine
----------------

### Pharmacokinetics and pharmacodynamics

Deutetrabenazine is a reversible VMAT-2 inhibitor. Similar to tetrabenazine, there are α and β enantiomers, and each gives rise to 2 isomers of a DHTBZ metabolite. However, the incorporation of deuterium, which is a stable, non-radioactive, non-toxic, and naturally occurring isotope of hydrogen, in place of hydrogen at the sites of primary metabolism results in slower metabolic clearance compared to tetrabenazine and lower Cmax values, despite similar effective doses as used in the tetrabenazine trials (36--48 mg). Deutetrabenazine should be taken with food and its bioavailability after oral administration is ≥80%. The half-life of deutetrabenazine is about 9--10 hours (thus twice-daily dosing is required),[@b1-dddt-12-1215] and its protein binding is close to 84%. Deutetrabenazine is extensively metabolized by CYP2D6, with minor contributions from CYP1A2 and CYP3A4/5, and 80% of it being eliminated in urine and around 10% in feces.

### Efficacy

One systematic review reported results from 2 acute trials and 1 open-label, long-term study.[@b42-dddt-12-1215] In 2017, the US FDA approved deutetrabenazine for both Huntington's disease and TD. One multicenter DBRPCT ("ARM-TD study") included 117 (deutetrabenazine =58, placebo =59) patients with moderate to severe TD (82.9% of which with AIMS ≥6 based on blinded video assessment), and assessed AIMS, clinician's and patient's global impression (CGI and PGI) scores after 12 weeks. Patients were administered deutetrabenazine starting from 12 mg/day, with weekly increases of 6 mg up to 48 mg maximum (36 mg for patients taking strong CYP2D6 inhibitors), according to clinical response. Baseline AIMS values were 9.6 (4.1 SD) with deutetrabenazine and 9.6 (3.8 SD) with placebo. Although no significant difference was noted in CGI scores compared with placebo at study endpoint, or in modified Craniocervical Dystonia Questionnaire (mCDQ-24) (*p* not available for both comparisons), AIMS scores improved significantly more with deutetrabenazine than placebo (place bo-subtracted treatment difference −1.4, standard error \[SE\]: 0.6, *p*=0.019).[@b56-dddt-12-1215] Another multicenter DBRPCT ("AIM-TD study") included 298 patients (deutetrabenazine =224 divided in 3 groups: 12, 24, and 36 mg/day; placebo =74) with TD (AIMS ≥6) duration ≥3 months, and assessed AIMS after 12 weeks (or at least at 1 follow-up observation).[@b57-dddt-12-1215] Baseline AIMS values were 9.6 (2.4 SD) with 12 mg/day deutetrabenazine, 9.4 (2.9 SD) with 24 mg/day, 10.1 (3.2 SD) with 36 mg/day, and 9.5 (2.7 SD) with placebo. Efficacy was demonstrated compared with placebo for deutetrabenazine 36 mg/day (placebo-subtracted treatment difference −1.9, SE: 0.58, *p*=0.001) and 24 mg/day (−1.8, SE: 0.60, *p*=0.003), but not for 12 mg/day (−0.7, SE: 0.57, *p*=0.217). Moreover, compared to placebo (12%), the proportion of patients with a ≥50% AIMS score reduction was significantly higher with deutetrabenazine 24 mg/day (35%, OR =3.96, 95% CI =1.46, 10.72, *p*=0.005) and 36 mg/day (33%, OR =3.80, 95% CI =1.40, 10.36, *p*=0.007). Conversely, in the ITT population, deutetrabenazine did not differ significantly from placebo regarding the Patient Global Impression of Change (PGIC) defined responder rate (12 mg/day: *p*=0.37, 24 mg/day: *p*=0.13, 36 mg/day: *p*=0.30) or mCDQ-24 scores (12 mg/day: *p*=0.66, 24 mg/day: *p*=0.24, 36 mg/day: *p*=0.12).[@b57-dddt-12-1215] In the OLE study[@b58-dddt-12-1215],[@b59-dddt-12-1215] (59 weeks, ongoing, n=304 from the ARM-TD and AIM-TD studies), all efficacy measures (continuous scores or responder rates) continued to improve from week 6 to week 54. No head to head comparison with other VMAT-2 inhibitors has been performed.

### Safety and tolerability

Deutetrabenazine was generally well tolerated, with trial completion rate ranging from 89% to 95% in DBRPCTs,[@b41-dddt-12-1215] and the NNH for all-cause discontinuation was not significantly different from placebo.[@b41-dddt-12-1215] Moreover, deutetrabenazine had similar AEs rates in all dose arms compared with placebo (36 mg/day: 51.4%; 24 mg/day: 43.8%; 12 mg/day: 48.6%; placebo: 47.2%), with the 36 mg/day dose being associated with the highest frequency of AEs.[@b57-dddt-12-1215] Moreover, no worsening of EPS occurred,[@b56-dddt-12-1215] yet such a definition should be replaced with finer definitions of specific adverse motor events, with consistent reporting of rates of each of them in RCTs.[@b60-dddt-12-1215] Sedation/somnolence may occur with deutetrabenazine, but the manufacturer correctly advises that patients with Huntington's disease should be advised about such a risk, while there is no such need in patients with TD, given the comparable rates of somnolence in the deutetrabenazine (2%--13.8%) and placebo group (4%--10.2%). Although deutetrabenazine, like tetrabenazine, has a black box warning for depression and suicidality in patients with Huntington's disease (based on data from trials in this population), data from 2 trials in patients with TD did not show any increased risk versus placebo, which is why deutetrabenazine did not receive such a regulatory warning for the TD population.[@b56-dddt-12-1215] In the ARM-TD trial, depressed mood/depression was noted at the exact same frequency as placebo (1.7%), with no patients reporting suicidality.[@b56-dddt-12-1215] In the AIM-TD trial, suicidality was reported in the 24 and 36 mg/day arms (2.7% the highest),[@b57-dddt-12-1215] but without any difference from placebo. Also, in the long-term, OLE study, deutetrabenazine showed[@b42-dddt-12-1215],[@b58-dddt-12-1215],[@b59-dddt-12-1215] similar adjusted incidences of AEs, compared with both the acute-phase trials and the placebo. Moreover, \>90% of psychiatric AEs were mild to moderate. Hence, the absence of any FDA warning about a putative increased risk of depression or suicide in patients with TD seems appropriate, at least in the included psychiatrically stable patients with TD. Deutetrabenazine has not been tested in the pediatric population.

### Poor metabolizers, special populations, and concomitant drugs

Poor CYP2D6 should be prescribed lower deutetrabenazine doses. No data are available about deutetrabenazine in patients with renal impairment. Even if no data are available, based on data for tetrabenazine, lower doses should be considered when hepatic function is impaired. Deutetrabenazine dose should also be decreased in the presence of CYP2D6 inhibitors (eg, paroxetine and fluoxetine). However, since the slower metabolism and lower Cmax reduce the impact of slow CYP2D6 metabolizers, no genotyping has been recommended, unlike for tetrabenazine.

Valbenazine
-----------

### Pharmacokinetics and pharmacodynamics

Valbenazine is a highly selective, reversible VMAT-2 inhibitor that consists of the (+)α-DHTBZ enantiomer, an oxidative metabolite of valbenazine, and its 2 isomers, with all 3 molecules having VMAT-2 binding only.[@b61-dddt-12-1215] It can be taken with or without food, although the C~max~ is decreased by high-fat meals. Oral bioavailability of valbenazine is \~49%, its half-life is about 20 hours,[@b62-dddt-12-1215] enabling once daily dosing, t~max~ is between 0.5 and 1.0 hours,[@b62-dddt-12-1215] steady state is reached within 8 days,[@b62-dddt-12-1215] and protein binding is 99%. Area under the curve (AUC) analyses have shown a dose-proportional increase from 50 to 150 mg/day and more than dose-proportion from 1 to 50 mg/day.[@b62-dddt-12-1215]

The affinity of valbenazine for VMAT-2 is Ki ≈150 nM, with virtually no affinity for VMAT-1 (Ki \>10,000 nM). Valbenazine and its metabolites do not have any affinity for other than VMAT-2 targets, namely, serotonin, dopamine, adrenergic, histaminergic, or muscarinic receptors, thus minimizing untoward effects beyond those specifically linked to its specific binding site. It is extensively metabo-lized by hydrolysis and oxidative metabolism (CYP3A4/5); (+)-α-HTBZ seems to be further metabolized in part by CYP2D6. Approximately 60% of elimination takes place in urine and 30% in feces.

### Efficacy

The US FDA approved valbenazine for TD in 2017.[@b63-dddt-12-1215] One systematic review[@b41-dddt-12-1215] has identified 6 completed trials (2 long-term extension studies and 4 DBRPCTs), including a total of 660 subjects, aged 18--85 years, with a study duration ranging from 12 days to 48 weeks, and with the valbenazine dose ranging from 12.5 to 100 mg/day. Four double-blind trials (NCT01393600,[@b64-dddt-12-1215] KINECT, KINECT 2, and KINECT 3)[@b41-dddt-12-1215],[@b65-dddt-12-1215]--[@b73-dddt-12-1215] and 1 dose-blind extension study (KINECT 4)[@b41-dddt-12-1215],[@b69-dddt-12-1215]--[@b72-dddt-12-1215] reported on the efficacy and safety of valbenazine,[@b41-dddt-12-1215],[@b68-dddt-12-1215]--[@b73-dddt-12-1215] in patients who developed TD during antipsychotic treatment for schizophrenia, schizoaffective disorder, or mood disorders, or during metoclopramide treatment for a gastrointestinal conditions.

Baseline AIMS scores in KINECT 2 were 8.0 (3.5 SD) in the valbenazine and 7.9 (4.5 SD) in the placebo group, being 10.4 (3.6) for 80 mg/day, 9.7 (4.1 SD) for 40 mg/day, and 9.9 (4.3 SD) for placebo in the KINECT 3 study.

Although valbenazine did not separate from placebo in the small dose-finding studies NCT01393600 (4 weeks, 37 patients in a blinded cross-over study, analyzed: drug =32, placebo =33) and KINECT (6 weeks, drug =50, placebo =54),[@b41-dddt-12-1215],[@b64-dddt-12-1215]--[@b67-dddt-12-1215] it showed significantly greater improvement in the AIMS total score compared to placebo at week 6 in 2 larger, acute-phase KINECT 2 (6 weeks, valbenazine: n=45, placebo n=44), and KINECT 3 trials (6 weeks, val-benazine: n=151, placebo: n=76, with extension to 48 weeks: n=198).[@b68-dddt-12-1215],[@b70-dddt-12-1215],[@b73-dddt-12-1215] In KINECT 2, improvement in total AIMS scores were consistently higher with valbenazine than placebo (treatment difference −2.4, SE: 0.7, *p*\<0.001), as well as CGI-TD score (treatment difference −0.8, SE: 0.2, *p*\<0.001). The same was true in KINECT 3 with regard to the AIMS score change (80 mg/day: −3.2, SE: 0.4, *p*\<0.001; 40 mg/day: −1.9, SE: 0.4, *p*\<0.001, vs placebo −0.1, SE: 0.4).

Valbenazine also outperformed placebo in response rates, regardless of the definition of response. For example, in KINECT 2, a ≥50% AIMS total score reduction was observed in 48.9% with valbenazine versus 18.2% with placebo (*p*\<0.001), with rates of patients achieving a CGI-TD ≤2 (ie, "much or very much improved") being 67% with valbenazine and 16% with placebo (*p*\<0.001).[@b41-dddt-12-1215] Similarly, in KINECT 3, a ≥50% AIMS total score reduction was observed in 40.0% with valbenazine 80 mg/day (*p*\<0.001), 23.8% with 40 mg/day (*p*=0.02), and 8.7% with placebo, with the 80 mg/day dose consistently showing the highest response rates.[@b41-dddt-12-1215],[@b68-dddt-12-1215]--[@b73-dddt-12-1215] Notably, the same efficacy and dose-related profile was confirmed in both the schizophrenia and schizoaffective disorder subgroup,[@b69-dddt-12-1215] as well as the mood disorder subgroup.[@b72-dddt-12-1215]

The NNT for treatment response was consistently around 4 for valbenazine 80 mg daily, ranging from 2 to 9, with doses from 25 to 75 mg/day. In KINECT 3, the NNT for the AIMS-based response in all patients was 4 for 80 mg/day and 7 for 40 mg/day, being consistent in patients with mood disorders and schizophrenia/schizoaffective disorder (mood disorder subgroup: 80 mg/day: NNT =4 for AIMS-based definition and NNT =6 for CGI-TD, 40 mg/day: NNT =9 for AIMS and NNT =8 for CGI-TD; schizophrenia subgroup: 80 mg/day: NNT =4 for AIMS-based definition and NNT =17 for CGI-TD, 40 mg/day: NNT =6 for AIMS and NNT =10 for CGI-TD).[@b41-dddt-12-1215],[@b61-dddt-12-1215],[@b68-dddt-12-1215],[@b69-dddt-12-1215],[@b72-dddt-12-1215]

In exploratory analyses, statistical separation of valbenazine from placebo occurred as early as week 2 at 80 mg/day and did not differ according to sex, age, ethnicity, underlying main diagnosis, or TD baseline severity.[@b68-dddt-12-1215],[@b73-dddt-12-1215]

However, in KINECT 2, the PGIC-based (treatment success) response rate statistics were not reported, only showing numerically higher rates with valbenazine versus placebo (57.8% vs 31.8%, *p*=NA),[@b73-dddt-12-1215] and in KINECT 3, the endpoint CGI-TD score differences missed statistical significance (treatment difference −0.3, SE: 0.1, *p*=0.074).[@b68-dddt-12-1215]

In the OLE study (48 weeks, plus 4 weeks after valbenazine withdrawal, n=164), all efficacy measures (continuous scores or responder rates) continued to improve from week 6 to week 48, but then worsened until week 52 after valbenazine was discontinued, trending back to the acute baseline values, supporting the need for continuation treatment.[@b69-dddt-12-1215],[@b70-dddt-12-1215],[@b72-dddt-12-1215]

No "head to head" comparison with other VMAT-2 inhibitors or other agents has been performed.

### Safety and tolerability

Valbenazine was generally well tolerated,[@b41-dddt-12-1215] with comparable study completion rates on valbenazine and placebo (KINECT 2: valbenazine: 76%, placebo: 80%; KINECT 3: valbenazine 80 mg/day: 88.8%, valbenazine 40 mg/day: 82.9%, placebo: 91%). Furthermore, no detrimental effects were noted on core psychopathologic symptoms of the underlying mental condition,[@b41-dddt-12-1215] in both the acute and the long-term extension trials.[@b71-dddt-12-1215] In addition, there was no increase in suicidal behavior or depression noted, at least in the included psychiatrically stable patients. Calgary Depression Scale for Schizophrenia and Montgomery and Asberg Depression Rating Scale scores remained stable after treatment with valbenazine 40 and 80 mg/day in both the 6-week KINECT 3 trial[@b68-dddt-12-1215] and the KINECT 4 long-term tolerability trial.[@b71-dddt-12-1215]

Two potential tolerability concerns have been reported,[@b41-dddt-12-1215] namely, QTc prolongation and somnolence. However, QTc prolongation, which was modeled by the FDA, was not clinically relevant at regular doses[@b74-dddt-12-1215] and should be monitored particularly in those with QTc prolongation or other arrhythmias associated with QT prolongation. Nevertheless, no clinically relevant ECG alteration was noted in the acute 6-week and 48-week long-term trials.[@b41-dddt-12-1215],[@b71-dddt-12-1215] Moreover, although patients with TD experienced numerically higher rates of somnolence compared with placebo (KINECT 2: valbenazine: 5.9%, placebo: 2%, *p*=NA; KINECT 3: valbenazine: 5.3%, placebo: 3.9%, *p*=NA), the rates were very low. Interestingly, in all patients, decreased appetite was reported more frequently with valbenazine versus placebo (KINECT 2: valbenazine: 7.8%, placebo: 0%).[@b73-dddt-12-1215]

The most frequent long-term AEs in both schizophrenia/schizoaffective and mood disorder subsamples in the 48-week extension study were somnolence, urinary tract infections, and headache.[@b71-dddt-12-1215] Finally, a potential risk of dose-related prolactin, bilirubin, and alkaline phosphatase increase was noted as per the FDA evaluation, but was not observed in the acute trials, and no clinically relevant laboratory alteration was noted in the 48-week, long-term tolerability trial.[@b71-dddt-12-1215]

### Poor metabolizers, special populations, and concomitant drugs

Lower doses (ie, 40 mg/day) should be prescribed in patients with known slow CYP2D6 metabolizer status or intolerability to 80 mg/day.[@b41-dddt-12-1215] Patients with moderate to severe hepatic impairment should take the lower dose of valbenazine, and pregnant or lactating women should be advised of the potential risk for the fetus or newborn, even if no data about such risks in humans are available to date. As for renal impairment, no dose adjustment is required for mild to moderate renal impairment, while valbenazine should be avoided in case of severe renal failure since no data are available.[@b41-dddt-12-1215]

No dose adjustment is required in the elderly population, and no efficacy or safety data are currently available for pediatric populations.[@b41-dddt-12-1215] Valbenazine should not be prescribed with MAOIs, or strong CYP3A4 inducers (eg, carbamazepine, St John's wort, phenytoin, and rifampin) and should be prescribed at a reduced dose when given together with strong inhibitors of CYP2D6 (eg, paroxetine, fluoxetine, and quinidine) or CYP3A4 (eg, itraconazole, ketoconazole, and clarithromycin), and digoxin concentrations should be monitored when valbenazine is administered with digoxin, due to possible increase of blood levels of digoxin with concomitant administration.[@b41-dddt-12-1215] However, no genotyping has been recommended unlike for tetrabenazine. In the 48-week, long-term tolerability trial, no relevant interaction with ongoing concomitant medications was reported.[@b71-dddt-12-1215]

Quality of included studies
---------------------------

[Table 3](#t3-dddt-12-1215){ref-type="table"} reports the quality of included studies. According to the Cochrane Risk of Bias Tool, 5 out of 6 blinded trials had low risk of bias, while for 1 (NCT01393600), no detailed methodological information was available (unclear risk of bias).

Meta-analysis
-------------

Meta-analyses were performed for AIMS change (primary outcome), CGI-TD change, mCDQ-24 change, and treatment response based on AIMS (≥50% total score reduction), CGI-TD (score ≤2, "much improved" or "very much improved"), or PGI-C ("treatment success"). [Table 4](#t4-dddt-12-1215){ref-type="table"} summarizes the results of random effects meta-analysis for VMAT-2 inhibitors pooled together and for deutetrabenazine and valbenazine individually, and [Figure 2](#f2-dddt-12-1215){ref-type="fig"} presents the forest plot of AIMS change. All other forest plots and funnel plots of meta-analyses are available upon request.

Results confirmed the efficacy of VMAT-2 inhibitors for TD. AIMS scores reduced significantly more with VMAT-2 inhibitors as a class than placebo (trial arms k=8; SMD =−0.46, 95% CI =−0.28, −0.64, *p*\<0.001; WMD =−1.67, 95% CI =−1.07, −2.27; *p*\<0.001; I^2^=21%) and with both deutetrabenazine (k=4; SMD =−0.40, 95% CI =−0.19, −0.62, *p*\<0.001; WMD =−1.43, 95% CI =−0.67, −2,19; *p*\<0.001; I^2^=0%) and valbenazine (k=4; SMD =−0.58, 95% CI =−0.26, −0.91, *p*\<0.001; WMD =−2.07; 95% CI =−1.08, −3.05; *p*\<0.001; I^2^=50%) individually. VMAT-2 inhibitors as a class were superior for treatment response, defined according to AIMS (≥50% of AIMS score improvement from baseline) (k=8; RR =2.66; 95% CI =1.77, 3.99, *p*\<0.001; I^2^=0%; NNT =5, 95% CI =4, 8, *p*\<0.001). The same was true for deutetrabenazine (k=3; RR =2.13; 95% CI =1.10, 4.12; *p*=0.024; I^2^=0%; NNT =7, 95% CI =3, 333, *p*=0.046), and valbenazine (k=5; RR =3.05; 95% CI =1.81, 5.11; *p*\<0.001; I^2^=0%; NNT =4, 95% CI =3, 6, *p*\<0.001) individually. Similar results were found for VMAT-2 inhibitors as a class pertaining to response defined according to CGI criteria (k=9; RR =1.50; 95% CI =1.14, 1.97; *p*=0.003; I^2^=44.32%; NNT =6, 95% CI =3, 18, *p*=0.004), with consistent results for valbenazine (k=5; RR =2.06, 95% CI =1.24, 3.41; *p*=0.005; I^2^=59.96%; NNT =5, 95% CI =3, 62, *p*=0.034), while deutetrabenazine showed only a trend toward significance (k=4; RR =1.32; 95% CI =0.96,1.82; *p*=0.088; I^2^=0%; NNT =9, 95% CI =4, 200, *p*=0.041).

Deutetrabenazine and valbenazine were not significantly superior to placebo regarding the following secondary outcomes for which results were only available for one or the other VMAT-2 inhibitor. Deutetrabenazine: mCDQ-24 (k=4; *p*=0.157) and PGI-C response (k=4; *p*=0.149); valbenazine: CGI-TD scores change (k=6; *p*=0.953). Notably, when 12 mg group in AIM-TD trial was removed from analyses, a trend toward a significant improvement in mCDQ-24 appeared (*p*=0.079). Also, when deutetrabenazine 12 mg arm was removed from analyses, heterogeneity significantly dropped across the above-described analyses.

With regard to safety, a meta-analysis was performed for all adverse effects reported in the included data sources, and all results are reported in [Table 5](#t5-dddt-12-1215){ref-type="table"}. No increased risk of AEs versus placebo emerged with VMAT-2 inhibitors as a class or with deutetrabenazine or valbenazine individually. This non-differential adverse effect risk included no increased risk of depression, suicidal ideation, sedation, or somnolence, which had been a concern with tetrabenazine (but whose data could not be meta-analyzed due to insufficient trial design). In fact, VMAT-2 inhibitors were associated with a significantly lower risk of nausea compared with placebo (k=4, RR =0.31, 95% CI =0.10, 0.95, *p*=0.04).

Discussion
==========

Tetrabenazine, deutetrabenazine, and valbenazine inhibit VMAT-2 action, resulting in less dopamine being transported from the cytoplasm into presynaptic vesicles, which leads to less dopamine release from the pre-synaptic neurons into the synaptic cleft.[@b36-dddt-12-1215] This reduced dopamine release results in less stimulation of post-synaptic dopamine receptors in the nigrostriatal pathway, which is thought to subsequently decrease dyskinetic movements. Despite this common mechanism of action, pharmacological factors, efficacy, and safety should be considered when selecting a VMAT-2 inhibitor to treat TD, since any preference of one VMAT-2 inhibitor over another is currently based on individual medication properties, rather than on head-to-head comparison trials, which are still lacking.

Results of this systematic review and meta-analysis indicate that high-quality evidence for the efficacy and safety in patients with TD exists for the 2 FDA-approved VMAT-2 inhibitors, deutetrabenazine and valbenazine, but not for tetrabenazine. Furthermore, pharmacokinetic and also pharmacodynamic properties of VMAT-2 inhibitors differ. Tetrabenazine has a short half-life, needs to be given 3 times daily, leading to high peak levels and high peak--trough variations that seem to be responsible for off-target adverse effects, such as sedation/somnolence, acute motor syndromes, including parkinsonism and akathisia, QTc prolongation, and, possibly, depression and suicidality.[@b15-dddt-12-1215] In contrast, deutetrabenazine has a longer half-life, can be given twice daily and has less peak levels and peak--trough variation, which reduces its adverse effect risk, although it still gives rise to 4 active metabolites, 2 of which have weak dopamine receptor blocking properties.[@b42-dddt-12-1215] Valbenazine, on the other hand, has an even longer half-life, can be given once daily and is metabolized to +-(α)HTBZ with its 2 isomers, which each have highly selective VMAT-2 activity.[@b41-dddt-12-1215]

Regarding efficacy, both deutetrabenazine and valbenazine have demonstrated robust efficacy for the reduction of AIMS scores and, regarding treatment response,[@b41-dddt-12-1215],[@b42-dddt-12-1215],[@b56-dddt-12-1215]--[@b59-dddt-12-1215],[@b64-dddt-12-1215],[@b68-dddt-12-1215]--[@b73-dddt-12-1215] generally with higher doses producing greater efficacy and with medium effect sizes and clinically relevant NNTs of 2--9 for variously defined treatment response. In contrast to clinician-rated outcomes, patient-rated outcomes were less robust or nonsignificant. However, this reduced the ability to demonstrate superiority compared to placebo on patient-rated outcomes may have to do with the fact that not all patients are fully aware of the presence or impact of the TD.[@b75-dddt-12-1215]--[@b79-dddt-12-1215] In this context, data are missing that put the efficacy results into the context of patient awareness and burden caused by the TD, such as in subgroup analyses. To comprehensively assess the impact of TD and of treatments for TD, the field will have to define TD-specific rating scales that tap into the subjective and functional relevance of TD that may not necessarily be directly related to total TD severity, but also (rather) to local body area distribution and the functional impact of the abnormal involuntary movements.

Moreover, since, like with clozapine,[@b23-dddt-12-1215] discontinuation of valbenazine was associated with a general recurrence of TD, even after 48 weeks of treatment,[@b59-dddt-12-1215],[@b71-dddt-12-1215] it will be important to clarify if there is a subgroup of patients in whom TD does not recur after remission during VMAT-2 inhibitor treatment, be it those in whom dopamine blocking agents could be stopped, or in those with a short duration or milder or locally more limited forms of TD. Notably, effects of discontinuation have not yet been studied with deutetrabenazine, while observational studies have shown TD recurrence after withdrawal of tetrabenazine.[@b37-dddt-12-1215],[@b80-dddt-12-1215] Moreover, data are missing that could help to determine if starting a VMAT-2 inhibitor in patients with only subtle dyskinetic movements that are still below the threshold of Schooler--Kane criteria[@b81-dddt-12-1215] can effectively prevent progression to TD.

Different from tetrabenazine, the safety and tolerability of deutetrabenazine and valbenazine was very good. There was no increased treatment discontinuation versus placebo and no decrease in efficacy of the antipsychotics for the underlying psychiatric condition. Moreover, the QTc prolonging effects of VMAT-2 inhibitors seemed modest.[@b68-dddt-12-1215],[@b71-dddt-12-1215] Similarly, in patients with TD, parkinsonian side effects, akathisia, and somnolence/sedation were far less common with either deutetrabenazine (parkinsonian side effects: 0%--1%; akathisia: 0%--5.2%; sedation/somnolence: 0%--13.8%) or valbenazine (parkinsonian side effects: 0%--3.8%; akathisia: 0%--5.3%; sedation/somnolence: 0%--5.9%) than with tetrabenazine (parkinsonian side effects: 4.3%--78.6%; akathisia: 1.7%--9.5%; sedation/somnolence: 6%--31%), despite ongoing treatment with antipsychotics.

Importantly, due to results from studies in patients with, tetrabenazine has a black box warning for depression and suicidality. Based on the limited data in TD patients, tetrabenazine was still associated with depression in 6.8% (range 1.7%--11%) of patients. Conversely, neither depression nor suicidality emerged as a concern with deutetrabenazine or valbenazine, with placebo-level rates in the acute trials (deutetrabenazine: depression: 1%--4%; suicidality: 0%--3%; valbenazine: depression: 0%--1%; suicidality: 0%--4.2%) and illness base-rate frequencies[@b82-dddt-12-1215]--[@b85-dddt-12-1215] in the long-term studies lasting up to 1 year (deutetrabenazine: depression: 6%--20%; suicidality: 0%--13%; valbenazine: depression: 2.6%--3.2%; suicidality: 4.5%--4.5%). These reassuring results are reflected by an absence of a black box labeling by the FDA for both deutetrabenazine and valbenazine in the patient population with TD with regard to depression and suicidality. However, results are currently based on selected patient populations agreeing to participate in research studies. Since the vast majority of patients with TD (apart from those with gastrointestinal conditions and metoclopramide therapy) have an underlying psychiatric condition, mainly schizophrenia or schizoaffective disorder and mood disorders (roughly two-thirds and one-third in the valbenazine or deutetrabenazine trials, respectively), they have an illness-inherent risk for the emergence or worsening of depression and suicidality.[@b82-dddt-12-1215]--[@b85-dddt-12-1215] Therefore, despite the current absence of a signal for depression and suicidal behavior in the deutetrabenazine and valbenazine studies, clinicians need to monitor mood status and suicidality in patients on VMAT-2 inhibitors, be it illness related or as part of an adverse effect. Moreover, since patients with active major depression or suicidality were excluded from the regulatory trials with VMAT-2 inhibitors, their safety in these populations is currently unclear.

The results of this meta-analysis need to be interpreted within its strengths and limitations. This meta-analysis has the following strengths. First, to our knowledge, this is the first comprehensive meta-analysis assessing the efficacy and safety of deutetrabenazine and valbenazine in TD. Moreover, given the conservative choice not to consider post hoc analyses from individual publications (which yield significant results in single trials as opposed to some non-significant findings from ITT or prespecified mITT data[@b56-dddt-12-1215],[@b57-dddt-12-1215]), our significant results can be considered solid and unlikely be the result of a bias ([Table 4](#t4-dddt-12-1215){ref-type="table"}). Moreover, results were confirmed in diagnostic subgroups. Finally, central ratings by blinded evaluators, which was applied in all DBRPCTs included in the meta-analysis and in both extension studies with deutetrabenazine and valbenazine, provides an unbiased and methodologically superior outcome assessment.[@b86-dddt-12-1215]

However, some limitations should also be considered that are mainly due to the available evidence. Tetrabenazine essentially lacks sufficiently large and methodologically sound data from sufficiently large DBRPCTs to evaluate its utility in patients with TD. No RCT that compares different VMAT-2 inhibitors head-to-head currently exists. Moreover, all included trials evaluating the efficacy and safety of deutetrabenazine and valbenazine were industry-funded. However, results from this meta-analysis did not suggest the presence of any publication bias. Furthermore, results from patient-rated outcomes were inconsistent, and data on the functional impact of TD reduction with VMAT-2 inhibitors and information provided by family members/caregivers are lacking. Moreover, data regarding whether valbenazine or deutetrabenazine is effective in milder forms of TD are missing. Finally, patients included in the registration trials were psychiatrically stable and did not have active major depressive disorder or active suicidality (although patients with a history of suicidality were eligible for the studies). Thus, generalizability of the results to a more severely psychiatrically ill population with TD is currently not clear. Nevertheless, results from this meta-analysis confirm statistically and clinically relevant efficacy of deutetrabenazine and valbenazine in patients with TD, indicating their safety and tolerability in this important and previously underserved patient population.

Conclusion
==========

Deutetrabenazine and valbenazine are FDA approved for TD and have at present the best high-quality evidence supporting their efficacy for TD, at the dose of 24--36 mg/day for deutetrabenazine and 40--80 mg/day for valbenazine, likely with a positive dose--response relationship. Moreover, the efficacy seems to progress further beyond the acute 6--12 weeks, as treatment continues for up to 1 year, both in patients with schizophrenia or schizoaffective disorder and in patients with mood disorders. Both deutetrabenazine and valbenazine are safe, at least in the studied, psychiatrically stable patient populations, and according to meta-analytic results, neither of the 2 agents seems to have an increased risk for depression or suicidality in stable patients with TD.[@b86-dddt-12-1215]

Tetrabenazine has no high-quality evidence for its efficacy or safety in patients with TD and should, at best, be considered a third-line, off-label treatment for TD, unless until methodologically sound trials, ideally comparing tetrabenazine with other VMAT-2 inhibitors, show its evental non-inferiority regarding effiacy and tolerability compared with deutetrabenazine and valbenazine.

Additional RCTs with VMAT-2 inhibitors in patients with TD are needed, ideally targeting long-term safety in patients who are representative of clinical samples as well as targeting functionality and quality of life, rated by clinicians, patients, and family members/caregivers. Furthermore, head-to-head comparisons of the 2 FDA-approved agents should be conducted. In addition, studies should look to identify predictors of response and remission of TD as well as of subgroups in whom the VMAT-2 inhibitor may successfully be withdrawn after remission of TD.[@b50-dddt-12-1215] Finally, strategies for patients not responding sufficiently to the currently available VMAT-2 inhibitors also require further study.

Supplementary material
======================

###### 

Trials excluded with reasons

  Trial identifier on [ClinicalTrials.gov](https://clinicaltrials.gov/)   Drug               Reason for exclusion
  ----------------------------------------------------------------------- ------------------ ------------------------------------------
  NCT02509793                                                             Tetrabenazine      No tardive dyskinesia
  NCT01834911                                                             Tetrabenazine      No tardive dyskinesia
  NCT01133353                                                             Tetrabenazine      No tardive dyskinesia
  NCT00362804                                                             Tetrabenazine      No tardive dyskinesia
  NCT00219804                                                             Tetrabenazine      No tardive dyskinesia
  NCT00632645                                                             Tetrabenazine      No tardive dyskinesia
  NCT01451463                                                             Tetrabenazine      No tardive dyskinesia
  NCT01897896                                                             Tetrabenazine      No tardive dyskinesia
  NCT02844179                                                             Tetrabenazine      No tardive dyskinesia
  NCT01795859                                                             Tetrabenazine      No tardive dyskinesia
  NCT02236754                                                             Tetrabenazine      No tardive dyskinesia
  NCT02582736                                                             Tetrabenazine      No tardive dyskinesia
  NCT02138864                                                             Tetrabenazine      No tardive dyskinesia
  NCT02191358                                                             Tetrabenazine      No tardive dyskinesia
  NCT01734733                                                             Tetrabenazine      No tardive dyskinesia
  NCT00642057                                                             Tetrabenazine      No results available
  NCT01543321                                                             Tetrabenazine      Currently recruiting patients/no results
  NCT02736955                                                             Tetrabenazine      Currently recruiting patients/no results
  NCT01795859                                                             Deutetrabenazine   No tardive dyskinesia
  NCT02674321                                                             Deutetrabenazine   No tardive dyskinesia
  NCT01897896                                                             Deutetrabenazine   No tardive dyskinesia
  NCT02198794                                                             Deutetrabenazine   No results available
  NCT01910480                                                             Valbenazine        No tardive dyskinesia
  NCT01916993                                                             Valbenazine        No tardive dyskinesia
  NCT02879578                                                             Valbenazine        No tardive dyskinesia
  NCT02581865                                                             Valbenazine        No tardive dyskinesia
  NCT02679079                                                             Valbenazine        No tardive dyskinesia
  NCT02256475                                                             Valbenazine        No tardive dyskinesia
  NCT01267188                                                             Valbenazine        No results available
  NCT02736955                                                             Valbenazine        No results available
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![PRISMA flowchart of study selection process.^\*^\
**Notes:** ^\*^Different information from the same trial were retrieved from different sources (articles and result section of [ClinicalTrials.gov](https://clinicaltrials.gov/) for each trial). Hence, record selection flow diagram goes in parallel (articles and trials) with final merging of information from different sources in the present manuscript. Article represents published manuscript; study represents trial with design other than DBRPCT, or retrospective data collection; trial represents DBRPCT.\
**Abbreviation:** DBRPCT, double-blind randomized placebo-controlled trial.](dddt-12-1215Fig1){#f1-dddt-12-1215}

![Forest plot of AIMS change after treatment with deutetrabenazine and valbenazine.\
**Abbreviation:** AIMS, Abnormal Involuntary Movement Scale.](dddt-12-1215Fig2){#f2-dddt-12-1215}

###### 

Characteristics of studies included, comparing VMAT-2 inhibitors versus placebo for TD

  Study                                                                                                                                                                                         Sponsor                                                         Dose, mg/day                    Control             Design                                                                       Duration, weeks                                                                          N, drug                                 N, control   Age, years                                                  Male, %   Inclusion criteria                                                   Outcomes
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------- ------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------- ------------ ----------------------------------------------------------- --------- -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  **Tetrabenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Godwin-Austen et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                     NA                                                              25--100                         Placebo diazepam    Randomized, DB, controlled                                                   1                                                                                        6                                                    70--85                                                      NA        NA                                                                   Video recording, Likert scale
  Kazamatsuri et al[@b52-dddt-12-1215]                                                                                                                                                          NA                                                              50--150                                             OL                                                                           6                                                                                        24                                                   55; 30--81                                                  NA        NA                                                                   Blinded psychiatrist assessing oral movements only
  Kazamatsuri et al[@b53-dddt-12-1215]                                                                                                                                                          NA                                                              NA                              Haloperidol 4 mg    Randomized, controlled prospective                                           18                                                                                       13                                                   55.8; 41--63                                                NA        NA                                                                   Change of frequency of bucco-linguomasticatory oral dyskinesias
  Asher et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                             NA                                                              175 (25--200)                   Placebo             Randomized, single-blind, cross-over                                         ≥3 at optimal dose                                                                       12                                                   NA                                                          NA        NA                                                                   Likert scale
  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                          NA                                                              Max 200                         Placebo             Randomized DB, cross-over                                                    NA                                                                                       4                                                    NA                                                          NA        NA                                                                   Video recording
  Fahn et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                              NA                                                              25--300                                             OL                                                                           NA                                                                                       14                                                   NA                                                          NA        NA                                                                   Likert scale
  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                          NA                                                              25--100                                             OL                                                                           NA                                                                                       44                                                   NA                                                          NA        NA                                                                   Likert scale
  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                          NA                                                              Mean maximum 96.9 (25--400)     ±62                 OL                                                                           2.4 years(0.25 months to 14 years)                                                       93                                                   NA                                                          NA        NA                                                                   Likert scale
  Watson et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                            NA                                                              91.3±38.9                                           Case series                                                                  NA                                                                                       23                                                   NA                                                          NA        NA                                                                   Likert scale
  Ondo et al[@b54-dddt-12-1215]                                                                                                                                                                 NA                                                              25--150                                             OL                                                                           12                                                                                       20                                                   65.2; 23--82                                                NA        NA                                                                   Blinded video rater
  Paleacu et al (Leung and Breden)[@b15-dddt-12-1215]                                                                                                                                           NA                                                              76.2±38.4 (12.5--150)                               Retrospective review                                                         NA                                                                                       17                                                   NA                                                          NA        NA                                                                   CGIC
  Kenney et al[@b80-dddt-12-1215]                                                                                                                                                               NA                                                              60.4±35.7                                           Retrospective review                                                         2.3±3.4 years                                                                            149                                                  NA                                                          NA        NA                                                                   Likert scale
  12 Publications                                                                                                                                                                               All NA                                                          25--300                                             1 placebo and diazepam, 2 placebo, 1 haloperidol controlled, 5 OL, 3 other   From 1 week to 18 weeks for controlled trials, and up to 2.4 years in all studies        419                                                  23--82                                                      NA        NA                                                                   3 Video recording, 6 Likert scale, 1 CGI, 2 oral dyskinetic movements assessment
  **Deutetrabenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  NCT02195700 -- ARM-TD -- III -- 2017 (Fernandez et al)[@b56-dddt-12-1215]                                                                                                                     Auspex Pharmaceuticals, Inc.                                    38.8±7.9 (12--48)               Placebo             DBRPCT                                                                       12                                                                                       57                                      58           54.6                                                        47.9      TD                                                                   Centralized AIMS (video recorded), CGIC, PGIC, mCDQ-24, safety and tolerability
  NCT02291861 -- AIM-TD -- III -- 2017 (Anderson et al)[@b57-dddt-12-1215]                                                                                                                      Teva Pharmaceutical Industry                                    12 or 24 or 36                  Placebo             DBRPCT                                                                       12                                                                                       224                                     74           56.4                                                        45        TD                                                                   Centralized AIMS (video recorded), CGIC, PGIC, mCDQ-24, safety and tolerability
  NCT02198794 -- RIM-TD -- III -- 2017 (Citrome; Anderson et al; Anderson et al)[@b42-dddt-12-1215],[@b58-dddt-12-1215],[@b59-dddt-12-1215]                                                     Teva Pharmaceutical Industry                                    38.1±19.9                       --                  Single-arm, non-randomized, OL                                               59 (ongoing)                                                                             304                                     --           56.2                                                        44.4      TD (completers of AIM-TD and ARM-TD)                                 Centralized AIMS (video recorded), CGIC, PGIC, mCDQ-24, safety and tolerability
  3 Trials                                                                                                                                                                                      1 Auspex Pharmaceuticals, Inc, 2 Teva Pharmaceutical Industry   12--48                          2 placebo, 1 none   2 DBPRCT, 1 OL                                                               2 trials 12 weeks, 1 open-label study 159 weeks                                          585                                     132          55.7                                                        45.8      TD                                                                   2 Centralized AIMS (video recorded), CGIC, PGIC, mCDQ-24, safety and tolerability
  **Valbenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  NCT01393600 -- II -- 2012 -- Valbenazine (Citrome; [ClinicalTrials.gov](http://ClinicalTrials.gov))[@b41-dddt-12-1215],[@b64-dddt-12-1215]                                                    Neurocrine Biosciences, Inc                                     12.5 or 50                      Placebo             DB cross-over study                                                          4                                                                                        37 total (32 valbenazine, 33 placebo)                51.1; 18--65[\*](#tfn1-dddt-12-1215){ref-type="table-fn"}   59.5      Schizophrenia or schizoaffective disorder, and TD                    Centralized AIMS (video recorded), CGI-TD, PGIC, safety/tolerability, plasma concentrations
  NCT01688037 -- KINECT -- II -- 2013 -- Valbenazine (Citrome; FDA)[@b41-dddt-12-1215],[@b67-dddt-12-1215]                                                                                      Neurocrine Biosciences, Inc                                     100 × 2 weeks, followed by 50   Placebo             DBRPCT                                                                       6                                                                                        53                                      54           18--85[\*](#tfn1-dddt-12-1215){ref-type="table-fn"}         66.4      Schizophrenia or schizoaffective disorder, and TD                    Centralized AIMS (video recorded), AIMS responders, CGI-TD, PGIC, safety/tolerability, plasma concentrations
  NCT01733121 -- KINECT 2 -- II -- 2013 -- Valbenazine (Citrome; O'Brien et al; [ClinicalTrials.gov](https://clinicaltrials.gov/))[@b41-dddt-12-1215],[@b64-dddt-12-1215],[@b73-dddt-12-1215]   Neurocrine Biosciences, Inc                                     25--75                          Placebo             DBRPCT                                                                       6                                                                                        45                                      44           56.2; 18--85[\*](#tfn1-dddt-12-1215){ref-type="table-fn"}   57        Schizophrenia, schizoaffective, mood disorder, GI disorder, and TD   Centralized AIMS (video recorded), AIMS responders, CGI-TD, CGI-TD responders, PGIC safety/tolerability, plasma concentrations
  NCT02274558 -- KINECT 3 -- III -- 2016 (Citrome; Kane et al; Correll et al; Hauser et al; Factor et al)[@b41-dddt-12-1215],[@b68-dddt-12-1215]--[@b70-dddt-12-1215],[@b72-dddt-12-1215]       Neurocrine Biosciences, Inc                                     40 or 80                        Placebo             DBRPCT                                                                       6, plus 48 extension                                                                     151                                     76           56.1; 18--85[\*](#tfn1-dddt-12-1215){ref-type="table-fn"}   54.2      Schizophrenia, schizoaffective, mood disorder, and TD                Centralized AIMS (video recorded), AIMS responders, CGI-TD, CGI-TD responders, PGIC
  KINECT 3 and KINECT 4 (NCT02405091)[@b69-dddt-12-1215]--[@b72-dddt-12-1215] -- 2016 (Factor et al; Kane et al; Josiassen et al; Correl et al)[@b69-dddt-12-1215]--[@b72-dddt-12-1215]         Neurocrine Biosciences, Inc                                     40 or 80                        --                  Non-randomized OL                                                            48                                                                                       163                                     NA           NA                                                          NA        Schizophrenia, schizoaffective, mood disorder, and TD                Centralized AIMS (video recorded), PGIC, CGIC, safety, tolerability
  5 Trials                                                                                                                                                                                      All sponsored by Neurocrine Biosciences, Inc                    12.5--100                       4 placebo, 1 none   4 DB trials, 1 OL                                                            1 trial 4 weeks, 2 trials 6 weeks, 1 trial 6 plus 48 weeks extension, 1 study 48 weeks   444                                     207          54.6; 18--85                                                58.5      All schizophrenia, schizoaffective, mood disorder, and TD            4 centralized AIMS (video recorded), and other efficacy secondary outcomes, 5 safety and tolerability

**Note:**

Inclusion criteria.

**Abbreviations:** AEs, adverse effects; AIMS, Abnormal Involuntary Movement Scale; CGIC, Clinical Global Impression Change; Ctrl, control; DB, double-blind; DBRCT, double-blind randomized controlled trial; mCDQ, modified Craniocervical Dystonia Questionnaire; NA, not available; OL, open label; PGIC, Patient's Global Impression of Change; TD, tardive dyskinesia; TDIS, tardive dyskinesia impact scale.

###### 

Efficacy and safety in trials of VMAT-2 inhibitors for TD[\*](#tfn3-dddt-12-1215){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                                                                     Efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Safety/tolerability (AE ≥5%, serious AE)
  --------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tetrabenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Godwin-Austen et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                Mean change from baseline: PLC −0.5±1.1, diazepam −2.2 (1.0), tetrabenazine −3.6±1.6, on 4-point severity scale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Most common side effect was sedation, similar to sedation after diazepam administration, and 1 case of syncope. After tetrabenazine was discontinued, TD symptoms relapsed
   Randomized, placebo, and diazepam-controlled\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Sample size =6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Kazamatsuri et al[@b52-dddt-12-1215] (Leung and Breden)[@b15-dddt-12-1215]\                                                                               Remission of TD in 33%, marked reduction 25%, none worsened. From 30 oral movements per minute at baseline to 10.8 after 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Study was discontinued in 4 patients. Parkinsonism was not observed
   Open label\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kazamatsuri et al[@b53-dddt-12-1215] (Leung and Breden)[@b15-dddt-12-1215]\                                                                               After 2 weeks, haloperidol showed larger efficacy, but at week 12 no patients under haloperidol showed remission, while 2 patients on tetrabenazine showed remission of dyskinesia. Initial improvement after 2 weeks generally decreased in both arms (tetrabenazine and haloperidol). All dyskinetic symptoms relapsed after tetrabenazine discontinuation marked response in 33% patients, moderate response in 17%, no response in 33%                                                                                                                                                                                                                                                                                         NA\
   Randomized, haloperidol-controlled\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Well tolerated, no behavioral changes observed
   Sample size =13\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Asher et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Randomized, placebo-controlled, cross-over\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                     All patients improved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Adverse effects in 75% of patients: restlessness, drooling, gait change, parkinsonism, anxiety
   Randomized, placebo-controlled, cross-over\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Fahn et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                         Majority of patients (11/14) were considered responders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Parkinsonism in all patients except 1
   Open-label\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                     Score 1 in 6 patients, score 2 in 25 patients, score 3 in 11 patients, score 4 and 5 in 1 patient, respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    AE in \>10% were parkinsonism (24%), drowsiness (13%), and depression (11%)
   Open-label\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Jankovic et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                     Patients had mostly (89.3%) excellent response at first follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Most common side effects: drowsiness/fatigue (36.5%), parkinsonism (28.5%), depression (15%), insomnia (11%), anxiety (10.3%), akathisia (9.5%), nausea/vomiting (4.8%). 23% discontinued therapy due to adverse effects
   Open-label\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =93                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Watson et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                       78% of patients had a score of at least 3 or 4 at baseline, and 87% achieved a score of 0 or 1. All patients improved from baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adverse effects: drooling in 2 patients, parkinsonism in 1 patient
   Case series\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Sample size =23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ondo et al[@b54-dddt-12-1215] (Leung and Breden)[@b15-dddt-12-1215]\                                                                                      AIMS motor subset improved by 54.2%, and subjective AIMS improved by 60.4%. Marked improvement was reported by 11 patients, moderate improvement by 6 patients, and mild improvement in 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Parkinsonism was reported by 5 patients, sedation in 5 patients as well, and 1 elderly patient withdrawn the study because of sedation
   Open-label\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Sample size =20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Paleacu et al (Leung and Breden)[@b15-dddt-12-1215]\                                                                                                      1 patient showed a decrease in CGIC score, 4 showed no change, and 10 showed increase in CGIC score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Most common side effects: somnolence/weakness (6%), parkinsonism (2.5%), akathisia (1.7%), depression (1.7%)
   Retrospective\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Sample size =17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kenney et al[@b80-dddt-12-1215] (Leung and Breden)[@b15-dddt-12-1215]\                                                                                    Patients maintaining score of 1 or 2 to last follow-up: 83.5%, 85.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Most common side effects: drowsiness (25%), parkinsonism (15.4%), akathisia (7.6%), depression (7.6%)
   Retrospective\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Sample size =149                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Deutetrabenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  NCT02195700 -- ARM-TD -- week 12\                                                                                                                         After 12 weeks, deutetrabenazine improved AIMS score vs placebo (*p*=0.02). Responders were 48.2% with deutetrabenazine, 40.4% with placebo according to CGIC, and 42.9% vs 29.8% according to PGIC (no significant difference in both). No significant difference in mCDQ-24                                                                                                                                                                                                                                                                                                                                                                                                                                                      Any AE occurred in 48.3% vs 35.6% with placebo. Psychiatric AE rates were not different in deutetrabenazine compared with placebo; anxiety 3.4% vs 6.8%, depression 1.7% in both groups, and suicidal ideation in 0% vs 1.7%. No worsening in parkinsonism. No difference on QTc
  DBRPCT (Fernandez et al)[@b56-dddt-12-1215]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Sample size =69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Deutetrabenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  NCT02291861 -- AIM-TD -- week 12\                                                                                                                         After 12 weeks, deutetrabenazine improved AIMS score vs placebo, in a dose-related pattern (24 mg \[*p*=0.003\] or 36 mg \[*p*=0.001\] per day were effective). Responder rate according to AIMS (24 mg, 49%, *p*=0.006; 36 mg, 44%, *p*=0.032) or CGIC (24 mg, *p*=0.014; 36 mg, *p*=0.059 -- trend to significance) was higher with deutetrabenazine vs placebo (12% and 26%, respectively), while no significant difference was described as regards PGIC response or mCDQ-24 score difference                                                                                                                                                                                                                                  Any AE occurred with similar rates in deutetrabenazine (range 44%--51%) and placebo (47%). No difference in depression, somnolence, sedation, or suicidality
  DBRPCT (Anderson et al)[@b57-dddt-12-1215]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Sample size =298                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  NCT02198794 -- RIM-TD -- III -- 2017 (Citrome; Anderson et al; Anderson et al)[@b42-dddt-12-1215],[@b58-dddt-12-1215],[@b59-dddt-12-1215]                 At week 54, deutetrabenazine improved AIMS from baseline (*p*=NA), in both patient previously on deutetrabenazine and placebo. Responder rate as measured by CGIC increased from 58% at week 6 to 72% at week 54, and from 53% to 59% as measured by PGIC (*p*=NA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Exposure-adjusted incidence rates of AE were comparable or lower than short-term or placebo treatments. No cumulative toxicity was observed. Anxiety, somnolence, depression, suicidality, akathisia, restlessness, sedation, parkinsonism occurred at similar frequency to placebo and deutetrabenazine short-term treatment; 90% of psychiatric AE were mild to moderate in severity. 2 serious AE (1 attempted suicide), 4 deaths after drug withdrawal

  **Valbenazine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  NCT01393600 -- week 4\                                                                                                                                    After 4 weeks, valbenazine 12.5 mg was not superior to placebo on AIMS score mean difference (*p*=0.6), neither was 50 mg (*p*=0.4); 50 mg was superior after excluding data from one site involved in the multicenter study (*p*\<0.01). No statistical analysis provided for CGI-TD score                                                                                                                                                                                                                                                                                                                                                                                                                                        1 case of serious AE in 12.5 mg group only. Any other AE rate reported in placebo (11.4%); valbenazine 12.5 mg (23.5%), and 50 mg (31.6%). No specific AE occurred in \>1 patient in either valbenazine dose. No death
  DBRPCT (Citrome; [ClinicalTrials.gov](https://clinicaltrials.gov/))[@b41-dddt-12-1215],[@b64-dddt-12-1215]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  NCT01688037 -- KINECT -- week 6\                                                                                                                          After 6 weeks, AIMS (*p*=0.3), CGI-TD (*p*=0.7), or scores did not improve with valbenazine compared with placebo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 See below (KINECT 4) for analysis of safety and tolerability in an aggregated larger sample
  DBRPCT (Citrome; FDA)[@b41-dddt-12-1215],[@b67-dddt-12-1215]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  NCT01733121 -- KINECT 2 -- week 6\                                                                                                                        After 6 weeks, AIMS (*p*\<0.01), CGI-TD (*p*\<0.01), PGIC (*p*\<0.01), scores were improved from valbenazine 25 to 75 mg compared with placebo, and CGI-TD, PGIC response rates were 66.7% vs 15.9%, 57.8% vs 31.8% in valbenazine vs placebo (*p*=NA), respectively                                                                                                                                                                                                                                                                                                                                                                                                                                                               No serious AE with valbenazine, 2 serious AEs with placebo. Any AEs rate was 49% in subjects taking valbenazine and 33% in those under placebo. The most common AEs were fatigue and headache (each 9.8% vs 4.1% in placebo), constipation, and urinary tract infection (each 3.9% vs 6.1% in placebo). No clinically relevant alterations in laboratory examinations, ECG. No relevant variations in psychiatric symptoms were noted. No concerns were expressed about suicidal ideation, or depression. No parkinsonism or akathisia. No death in valbenazine, 1 death with placebo
  DBRPCT (Citrome; O'Brien et al; [ClinicalTrials.gov](https://clinicaltrials.gov/))[@b41-dddt-12-1215],[@b64-dddt-12-1215],[@b73-dddt-12-1215]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  NCT02274558 -- KINECT 3 -- week 6\                                                                                                                        After 6 weeks, AIMS score improved in both valbenazine 40 and 80 mg compared with placebo (*p*\<0.01), while CGI-TD scores improved in both valbenazine dose groups compared with placebo (*p*=0.01 both doses) (trend toward significance in all ITT population \[*p*=0.06, 80 mg; *p*=0.07, 40 mg\]. AIMS response rates were 40% in 80 mg (*p*\<0.001), 23.8% in 40 mg (*p*=0.02), 8.7% in placebo. In patients with mood disorders, AIMS (*p*\<0.05, 80 mg; *p*=0.002, 40 mg) and CGI-TD (*p*\<0.05, 80 mg; *p*=NA, 40 mg) scores improved in a dose-related pattern in valbenazine vs placebo, as well as response rate according to AIMS (38.5%, NNT =4 for 80 mg) or CGI-TD (34.6%, NNT =6 for 80 mg) criteria (*p*=NA).\   Any AE rate was 40.3% in 40 mg, 50.6% in 80 mg group, 43.4% in placebo group. Serious AE: 7.6% 80 mg, 5.6% 40 mg, 3.9% PLC. The most common AEs were somnolence (5.1% 80 mg, 5.6% 40 mg, vs 3.9% placebo), akathisia (2.5% 80 mg, 4.2% 40 mg vs 1.3% placebo), and dry mouth (0% 80 mg, 6.9% 40 mg, vs 1.3% placebo). 1 patient died in 80 mg group. Worsening of suicidal ideation rates did not differ from placebo (1.3% 80 mg, 4.2% 40 mg, vs 5.3% PLC). No relevant laboratory alteration
  DBRPCT (Citrome; Kane et al; Correll et al; Hauser et al; Factor et al)[@b41-dddt-12-1215],[@b68-dddt-12-1215]--[@b70-dddt-12-1215],[@b72-dddt-12-1215]   In patients with schizophrenia or schizoaffective disorder, AIMS (*p*\<0.01 for both doses) and CGI-TD (*p*=NA) scores improved in a dose-related pattern in valbenazine vs placebo, as well as response rates according to AIMS (40.9%, NNT =4 for 80 mg) or CGI-TD criteria (29.5%, NNT =17 for 80 mg) (*p*=NA)                                                                                                                                                                                                                                                                                                                                                                                                                  

  NCT02405091 -- KINECT, KINECT 3, KINECT 4 -- week 48\                                                                                                     In both patients with mood disorders and schizophrenia/schizoaffective disorder AIMS and CGI-TD scores, valbenazine showed continued and progressive improvement from baseline to week 48, with return toward baseline values at week 52 after valbenazine discontinuation (*p*=NA). At week 48, response rates showed the same improvement with a dose-related pattern, according to AIMS (56%, 80 mg) or CGI-TD (80%, 80 mg) criteria in mood disorders, and (50%, 80 mg) or (73.7%, 80 mg) in patients with schizophrenia (*p*=NA)                                                                                                                                                                                              Data from KINECT (n=46), KINECT 3 (n=220), and KINECT 4 (n=164) were pooled in 430 subjects, and AE reported at week 48. Any TEAE rate was 66.5%, with 14.7% discontinuation due to AE. TEAE rate was 64.4% in schizophrenia/schizoaffective disorder and 71.9% in mood disorders. The most common AEs in schizophrenia/schizoaffective were urinary tract infection (6.1%), headache (5.8%), and somnolence (5.2%). The most common AEs in mood disorders were headache (12.4%), urinary tract infections (10.7%), and somnolence (9.1%). Psychiatric symptoms did not change with the administration of valbenazine, according to PANSS, CDSS, MADRS, and YMRS scales in both diagnostic groups. Suicidal ideation rate in patients under valbenazine was 5%, similar to that with placebo in KINECT 3 (5.3%). Extrapyramidal symptoms were minimal. Rare, minimal, and non-clinically significant alterations were noted in laboratory parameters and ECG
  OL (Factor et al; Kane et al; Josiassen et al; Correl et al)[@b69-dddt-12-1215]--[@b72-dddt-12-1215]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Data adapted and expanded from Leung and Breden.[@b15-dddt-12-1215]

**Abbreviations:** AE, adverse event; AIMS, Abnormal Involuntary Movement Scale; CGI, Clinical Global Impression; mCDQ, modified Craniocervical Dystonia Questionnaire; NA, not assessed; PGIC, Patient's Global Impression of Change; TD, tardive dyskinesia; TEAE, treatment-emergent adverse event; VMAT, vesicular monoamine transporter; PANSS, Positive and Negative Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; MADRS, Montgomery and Asberg Depression Rating Scale; YMRS, Young Mania Rating Scale.

###### 

Risk of bias in randomized blinded trials comparing valbenazine or deutetrabenazine versus placebo for tardive dyskinesia

  Drug (study)                                                                                                                                       Trial                     Adequate sequence generation                                                                       Allocation concealment   Blinding (participants and personnel)   Blinding (outcome assessment)   Incomplete outcome data addressed   Free of selective reporting   Free of other bias   Summary assessment
  -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------- ------------------------ --------------------------------------- ------------------------------- ----------------------------------- ----------------------------- -------------------- --------------------
  Deutetrabenazine (Anderson et al)[@b57-dddt-12-1215]                                                                                               NCT02291861 -- AIM-TD     Low                                                                                                Low                      Low                                     Low                             Low                                 Low                           Low                  Low
  Deutetrabenazine (Fernandez et al)[@b56-dddt-12-1215]                                                                                              NCT02195700 -- ARM-TD     Low                                                                                                Low                      Low                                     Low                             Low                                 Low                           Low                  Low
  Valbenazine (FDA)[@b39-dddt-12-1215]                                                                                                               NCT01688037 -- KINECT     Low                                                                                                Low                      Low                                     Low                             Low                                 Low                           Low                  Low
  Valbenazine (Citrome; O'Brien et al; [ClinicalTrials.gov](http://ClinicalTrials.gov))[@b41-dddt-12-1215],[@b64-dddt-12-1215],[@b73-dddt-12-1215]   NCT01733121 -- KINECT 2   Low                                                                                                Low                      Low                                     Low                             Low                                 Low                           Low                  Low
  Valbenazine (Citrome; Correll et al; Hauser et al; Kane et al)[@b41-dddt-12-1215],[@b68-dddt-12-1215],[@b69-dddt-12-1215],[@b72-dddt-12-1215]      NCT02274558 -- KINECT 3   Low                                                                                                Low                      Low                                     Low                             Low                                 Low                           Low                  Low
  Valbenazine ([ClinicalTrials.gov](http://ClinicalTrials.gov))[@b64-dddt-12-1215]                                                                   NCT01393600               Unclear                                                                                            Unclear                  Unclear                                 Unclear                         Unclear                             Unclear                       Unclear              Unclear
  Summary                                                                                                                                                                      5 out of 6 DBRPCT had low risk of bias; it was not possible to collect information for one trial                                                                                                                                                                                           

###### 

Random effects meta-analysis of efficacy outcomes in trials comparing deutetrabenazine or valbenazine versus placebo for tardive dyskinesia

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                                                       No studies/study arms       No drugs       No placebo       SMD      95% CI\       95% CI\       *p*-value       Heterogeneity I^2^       WMD       95% CI\       95% CI\       *p*-value       Heterogeneity I^2^       Publication bias (Y/N); subgroup difference
                                                                                                                                                     LL            UL                                                               LL            UL                                                     
  ----------------------------------------------------------------------------- --------------------------- -------------- ---------------- -------- ------------- ------------- --------------- ------------------------ --------- ------------- ------------- --------------- ------------------------ -------------------------------------------------
  **Continuous outcomes**                                                                                                                                                                                                                                                                                

  AIMS total score change                                                                                                                                                                                                                                                                                

   Deutetrabenazine                                                             2/4                         281            132              −0.40    −0.19         −0.62         \<0.001         0%                       −1.43     −0.67         −2.19         \<0.001         0                        

   Valbenazine                                                                  3/4                         247            174              −0.58    −0.26         −0.91         \<0.001         61.24%                   −2.07     −1.08         −3.05         \<0.001         50                       

  Pooled VMAT-2 inhibitors                                                      5/8                         528            306              −0.46    −0.28         −0.64         \<0.001         31.73%                   −1.67     −1.07         −2.27         \<0.001         21.08                    N; N

  CGI-TD change (valbenazine)                                                   4/6                         279            208              −0.04    0.14          −0.22         0.67            0                        0.01      −0.21         0.22          0.953           0                        N

  mCDQ-24 change (deutetrabenazine)                                             2/4                         281            132              −0.15    0.06          −0.36         0.16            0                        −2.49     −5.96         0.95          0.16            0                        N

                                                                                                                                                                                                                                                                                                         

                                                                                **No studies/study arms**   **No drugs**   **No placebo**   **RR**   **95% CI**\   **95% CI**\   ***p*-value**   **Heterogeneity I^2^**   **NNT**   **95% CI**\   **95% CI**\   ***p*-value**   **Heterogeneity I^2^**   **Publication bias (Y/N); subgroup difference**
                                                                                                                                                     **LL**        **UL**                                                           **LL**        **UL**                                                 

                                                                                                                                                                                                                                                                                                         

  **Categorical outcomes**                                                                                                                                                                                                                                                                               

  Response (≥50% AIMS reduction)                                                                                                                                                                                                                                                                         

   Deutetrabenazine                                                             1/3                         224            75               2.13     1.10          4.12          0.024           0                        7         3             333           0.046           57.78                    

   Valbenazine                                                                  2/5                         196            120              3.05     1.81          5.11          \<0.001         0                        4         3             6             \<0.001         0                        

  Pooled VMAT-2 inhibitors                                                      3/8                         420            195              2.66     1.77          3.99          \<0.001         0                        5         4             8             \<0.001         36.12                    N; N

  CGI-TD response ("much improved" or "very much improved")                                                                                                                                                                                                                                              

   Deutetrabenazine                                                             2/4                         222            107              1.32     0.96          1.82          0.088           0                        9         4             200           0.041           0                        

   Valbenazine                                                                  2/5                         221            130              2.06     1.24          3.41          0.005           59.96                    5         3             62            0.034           76.32                    

  Pooled VMAT-2 inhibitors                                                      4/9                         443            237              1.50     1.14          1.97          0.003           44.32                    6         3             18            0.004           63.52                    N; N

  PGI-C response (deutetrabenazine) ("much improved" or "very much improved")   1/4                         281            132              1.40     0.89          2.21          0.15            0                        14        6             38            0.15            0                        N
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Response definition: AIMS, ≥50% reduction AIMS; CGI-TD, ≤2 at CGI-TD; PGI-C, treatment success.

**Abbreviations:** AIMS, Abnormal Involuntary Movement Scale; CGI, Clinical Global Impression; CI, confidence interval; mCDQ-24, modified Craniocervical Dystonia Questionnaire; NNT, number-needed-to-treat; PGI-C, Patient's Global Impression of Change; RR, risk ratio; SMD, standardized mean difference; VMAT, vesicular monoamine transporter; WMD, weighted mean difference; Y, yes; N, no; LL, lower limit; UL, upper limit; CGI-TD, Global Impression -- Tardive Dyskinesia.

###### 

Random effects meta-analysis of main safety outcomes in trials comparing deutetrabenazine or valbenazine versus placebo for tardive dyskinesia

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                        No studies/study arms   No drugs   No placebo   RR     95% CI\   95% CI\      *p*-value   Heterogeneity I^2^   NNH        95% CI\   95% CI\   *p*-value   Heterogeneity I^2^   Publication bias (Y/N); subgroup difference
                                                                                                        LL        UL                                                       LL        UL                                         
  ---------------------------------------------- ----------------------- ---------- ------------ ------ --------- ------------ ----------- -------------------- ---------- --------- --------- ----------- -------------------- ---------------------------------------------
  **General**                                                                                                                                                                                                                   

  Any AE                                                                                                                                                                                                                        

   Deutetrabenazine                              2/4                     280        131          1.09   0.90      1.32         0.37        0                    23         −16       7         0.42        0                    

   Valbenazine                                   4/6                     291        213          1.26   0.96      1.66         0.09        7.83                 11         43        6         **0.01**    0                    

   Pooled VMAT-2 inhibitors                      6/710                   571        344          1.15   0.98      1.34         0.09        0                    13         53        7         **0.01**    0                    N; N

  Death                                                                                                                                                                                                                         

   Deutetrabenazine                              2/4                     280        131          0.84   0.09      7.76         0.87        0                    \>1,000    −125      111       0.93        0                    

   Valbenazine                                   4/6                     291        213          0.70   0.08      6.04         0.74        0                    \<−1,000   −143      143       0.99        0                    

   Pooled VMAT-2 inhibitors                      6/10                    571        344          0.76   0.16      3.59         0.73        0                    \>1,000    −200      167       0.96        0                    N; N

  Discontinuation due to AE                                                                                                                                                                                                     

   Deutetrabenazine                              2/4                     274        131          1.01   0.29      3.52         0.99        0                    −1,000     −27       29        0.95        0                    

   Valbenazine                                   2/3                     202        125          1.05   0.34      3.26         0.93        0                    −45        −15       45        0.33        0                    

   Pooled VMAT-2 inhibitors                      4/7                     476        256          1.03   0.44      2.39         0.94        0                    −100       −26       56        0.50        0                    N; N

  Dose reduction due to AE (deutetrabenazine)    2/4                     280        131          1.84   0.59      5.73         0.29        0                    333        −91       59        0.33        0                    N; NA

  Dose suspension due to AE (deutetrabenazine)   2/4                     280        131          0.61   0.21      1.79         0.37        0                    −62        −18       43        0.44        0                    N; NA

  Serious AE                                                                                                                                                                                                                    

   Deutetrabenazine                              2/4                     280        131          0.76   0.32      1.78         0.52        0                    −62        −15       29        0.54        0                    

   Valbenazine                                   4/6                     291        213          1.57   0.56      4.39         0.39        0                    333        −71       48        0.70        0                    

   Pooled VMAT-2 inhibitors                      6/10                    571        344          1.02   0.53      1.96         0.96        0                    1,000      −67       56        0.87        0                    N; N

  TEAE (deutetrabenazine)                        2/4                     280        131          0.95   0.63      1.43         0.81        28.84                −67        −8        11        0.78        21.30                N; NA

  **Psychiatric**                                                                                                                                                                                                               

  Anxiety                                                                                                                                                                                                                       

   Deutetrabenazine                              2/4                     280        131          0.82   0.27      2.48         0.73        0                    −250       −23       28        0.49        0                    

   Valbenazine                                   1/2                     151        76           1.99   0.22      17.73        0.54        0                    53         −62       19        0.46        0                    

   Pooled VMAT-2 inhibitors                      3/6                     431        207          0.98   0.37      2.64         0.97        0                    111        −59       28        0.50        0                    N; N

  Depressed mood (deutetrabenazine)              2/4                     280        131          1.57   0.17      14.45        0.69        0                    1,000      −111      91        0.84        0                    N; NA

  Depression                                                                                                                                                                                                                    

   Deutetrabenazine                              2/4                     279        131          0.89   0.18      4.30         0.89        0                    250        −40       30        0.79        0                    

   Valbenazine                                   1/1                     51         49           1.00   0.00      24,910       1.00        NA                   \>1,000    −83       83        1.00        NA                   

   Pooled VMAT-2 inhibitors                      3/5                     330        180          0.89   0.19      4.26         0.89        0                    1,000      −91       83        0.92        0                    N; N

  Insomnia                                                                                                                                                                                                                      

   Deutetrabenazine                              1/1                     58         59           4.06   0.47      35.14        0.20        0                    19         −48       8         0.16        0                    

   Valbenazine                                   1/2                     151        76           1.48   0.15      14.47        0.74        0                    167        −37       26        0.73        0                    

   Pooled VMAT-2 inhibitors                      2/3                     209        135          2.52   0.52      12.08        0.25        0                    71         62.5      23        0.37        0                    N; N

  Suicidal ideation                                                                                                                                                                                                             

   Deutetrabenazine                              2/4                     280        131          0.83   0.14      4.99         0.84        0                    \>1,000    −77       77        0.98        0                    

   Valbenazine                                   3/4                     256        178          0.53   0.13      2.11         0.37        0                    −1,000     −111      125       0.89        0                    

   Pooled VMAT-2 inhibitors                      5/8                     536        309          0.63   0.21      1.87         0.40        0                    \<−1,000   −125      143       0.91        0                    N; N

  **Central nervous system**                                                                                                                                                                                                    

  Dizziness                                                                                                                                                                                                                     

   Deutetrabenazine                              1/1                     58         59           0.67   0.11      3.87         0.65        0                    −59        −111      18        0.65        NA                   

   Valbenazine                                   1/1                     51         49           0.19   0.01      3.89         0.28        0                    −24        −9        40        0.22        NA                   

   Pooled VMAT-2 inhibitors                      2/2                     109        108          0.48   0.11      2.22         0.35        0                    −33        −13       53        0.23        0                    NA; N

  Fatigue                                                                                                                                                                                                                       

   Deutetrabenazine                              2/4                     280        131          1.02   0.33      3.13         0.98        0                    91         −56       25        0.45        0                    

   Valbenazine                                   4/6                     291        213          2.21   0.67      7.26         0.19        0                    125        −56       29        0.54        0                    

   Pooled VMAT-2 inhibitors                      6/10                    571        344          1.47   0.65      3.32         0.36        0                    10         −10       34        0.34        0                    N; N

  Sedation                                                                                                                                                                                                                      

   Deutetrabenazine                              1/3                     222        72           4.32   0.00      12,788.00    0.72        0                    333        −100      67        0.68        22.69                

   Valbenazine                                   2/3                     86         84           1.79   0.26      12.22        0.55        0                    250        −23       20        0.88        0                    

   Pooled VMAT-2 inhibitors                      3/6                     308        156          1.88   0.29      12.16        0.51        0                    333        −111      71        0.66        0                    N; N

  Somnolence                                                                                                                                                                                                                    

   Deutetrabenazine                              2/4                     280        131          0.64   0.20      2.06         0.46        0                    −43        −15       44        0.33        0                    

   Valbenazine                                   4/6                     291        213          2.02   0.71      5.75         0.19        0                    111        −111      37        0.32        0                    

   Pooled VMAT-2 inhibitors                      6/10                    571        344          1.21   0.55      2.63         0.63        0                    200        −83       45        0.58        0                    N; N

  **Movement**                                                                                                                                                                                                                  

  Akathisia                                                                                                                                                                                                                     

   Deutetrabenazine                              2/4                     280        131          2.60   0.31      21.92        0.38        0                    500        −111      83        0.77        0                    

   Valbenazine                                   2/4                     186        111          2.66   0.32      21.99        0.36        0                    167        −83       42        0.52        0                    

   Pooled VMAT-2 inhibitors                      4/8                     466        242          2.63   0.58      11.79        0.21        0                    333        −167      91        0.57        0                    N; N

  Dyskinesia                                                                                                                                                                                                                    

   Deutetrabenazine                              1/3                     222        72           0.83   0.09      8.05         0.87        0                    1,000      −77       67        0.89        0                    

   Valbenazine                                   1/3                     151        76           3.20   0.18      55.83        0.42        0                    125        −45       26        0.59        38.51                

   Pooled VMAT-2 inhibitors                      2/6                     373        148          1.40   0.24      8.29         0.71        0                    500        −10       67        0.73        0                    N; N

  Parkinsonism                                                                                                                                                                                                                  

   Deutetrabenazine                              1/3                     222        72           2.46   0.00      7,563.62     0.83        0                    1,000      −125      91        0.80        0                    

   Valbenazine                                   1/1                     51         49           1      0.00      240,910.27   1.00        0                    \>1,000    −83       83        1.00        0                    

   Pooled VMAT-2 inhibitors                      2/4                     273        121          1.88   0.00      1,592.92     0.85        0                    1,000      −143      125       0.84        0                    N; N

  **Pain**                                                                                                                                                                                                                      

  Arthralgia (valbenazine)                       2/3                     205        129          2.63   0.43      15.86        0.29        0                    59         −77       21        0.27        0                    N; NA

  Back pain (valbenazine)                        2/3                     86         84           1.88   0.26      13.84        0.53        0                    10         −21       15        0.73        9.63                 N; NA

  Headache                                                                                                                                                                                                                      

   Deutetrabenazine                              2/4                     280        131          0.73   0.32      1.69         0.46        0                    −55        −14       29        0.49        0                    

   Valbenazine                                   3/5                     237        160          1.46   0.51      4.22         0.48        0                    500        −29       26        0.92        0                    

   Pooled VMAT-2 inhibitors                      5/9                     517        291          0.95   0.49      1.84         0.89        0                    −200       −29       40        0.76        0                    N; N

  **Anticholinergic**                                                                                                                                                                                                           

  Dry mouth                                                                                                                                                                                                                     

   Deutetrabenazine                              2/4                     280        131          0.64   0.18      2.24         0.49        0                    333        −40       31        0.82        25.88                

   Valbenazine                                   2/3                     202        125          2.42   0.33      17.49        0.38        20.47                34         −48       13        0.26        44.72                

   Pooled VMAT-2 inhibitors                      4/7                     109        108          0.94   0.33      2.70         0.90        0                    10         −67       29        0.45        33.14                N; N

  **Gastrointestinal**                                                                                                                                                                                                          

  Diarrhea                                                                                                                                                                                                                      

   Deutetrabenazine                              2/4                     280        131          1.11   0.37      3.33         0.85        0                    250        −28       23        0.83        0                    

   Valbenazine                                   1/2                     35         35           0.63   0.08      4.90         0.66        0                    −32        −7        13        0.57        0                    

   Pooled VMAT-2 inhibitors                      3/6                     315        166          0.98   0.37      2.58         0.97        0                    1,000      −27       27        0.99        0                    N; N

  Nausea                                                                                                                                                                                                                        

   Deutetrabenazine                              1/3                     222        72           0.10   0.02      0.44         **0.00**    0                    −11        −6        −53       **0.01**    0                    

   Valbenazine                                   1/1                     51         49           1.44   0.25      8.22         0.68        0                    56         −15       10        0.68        0                    

   Pooled VMAT-2 inhibitors                      2/4                     273        121          0.31   0.10      0.95         **0.04**    42.57                −22        −10       125       0.10        18.65                N; N

  Vomiting                                                                                                                                                                                                                      

   Deutetrabenazine                              1/1                     58         59           0.33   0.03      3.15         0.34        0                    −29        −10       32        0.31        0                    

   Valbenazine                                   3/5                     238        160          4.01   0.73      22.15        0.11        0                    250        −111      59        0.53        11.49                

   Pooled VMAT-2 inhibitors                      4/6                     296        219          1.61   0.41      6.27         0.49        0                    333        −100      67        0.68        12.35                N; N

  **Infections**                                                                                                                                                                                                                

  Respiratory infection                                                                                                                                                                                                         

   Deutetrabenazine                              1/1                     58         59           0.67   0.11      3.87         0.65        0                    −59        −11       18        0.65        0                    

   Valbenazine                                   2/3                     89         88           2.74   0.14      54.97        0.51        0                    \>1,000    −100      91        0.96        0                    

   Pooled VMAT-2 inhibitors                      3/4                     147        147          0.96   0.21      4.36         0.95        0                    \<−1,000   −100      100       0.99        0                    N; N

  Urinary infection (valbenazine)                4/6                     291        213          0.60   0.21      1.73         0.34        0                    −333       −48       71        0.71        0                    N; NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Bold entries indicate subtitles and significant findings (*p*\<0.05).

**Abbreviations:** AE, adverse events; NA, not assessed; NNH, number-need-to-harm; RR, risk ratio; TEAE, treatment-emergent adverse events; VMAT, vesicular monoamine transporter; Y, yes; N, no; LL, lower limit; UL, upper limit; N, no; Y, yes.
